251 related articles for article (PubMed ID: 32179677)
1. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.
Thiabaud G; He G; Sen S; Shelton KA; Baze WB; Segura L; Alaniz J; Munoz Macias R; Lyness G; Watts AB; Kim HM; Lee H; Cho MY; Hong KS; Finch R; Siddik ZH; Arambula JF; Sessler JL
Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7021-7029. PubMed ID: 32179677
[TBL] [Abstract][Full Text] [Related]
2. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
Thiabaud G; McCall R; He G; Arambula JF; Siddik ZH; Sessler JL
Angew Chem Int Ed Engl; 2016 Oct; 55(41):12626-31. PubMed ID: 27377046
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: synthesis and comparison with carboplatin in normal and Pt-resistant cell lines.
Arambula JF; Sessler JL; Fountain ME; Wei WH; Magda D; Siddik ZH
Dalton Trans; 2009 Dec; (48):10834-40. PubMed ID: 20023913
[TBL] [Abstract][Full Text] [Related]
4. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Dhar S; Kolishetti N; Lippard SJ; Farokhzad OC
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1850-5. PubMed ID: 21233423
[TBL] [Abstract][Full Text] [Related]
6. Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.
Henke H; Kryeziu K; Banfić J; Theiner S; Körner W; Brüggemann O; Berger W; Keppler BK; Heffeter P; Teasdale I
Macromol Biosci; 2016 Aug; 16(8):1239-1249. PubMed ID: 27169668
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
[TBL] [Abstract][Full Text] [Related]
8. Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.
Arambula JF; Sessler JL; Siddik ZH
Bioorg Med Chem Lett; 2011 Mar; 21(6):1701-5. PubMed ID: 21345675
[TBL] [Abstract][Full Text] [Related]
9. A Pt(IV)-conjugated brain penetrant macrocyclic peptide shows pre-clinical efficacy in glioblastoma.
Jimenez-Macias JL; Lee YC; Miller E; Finkelberg T; Zdioruk M; Berger G; Farquhar CE; Nowicki MO; Cho CF; Fedeles BI; Loas A; Pentelute BL; Lawler SE
J Control Release; 2022 Dec; 352():623-636. PubMed ID: 36349615
[TBL] [Abstract][Full Text] [Related]
10. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
11. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy.
Fu Y; Kong Y; Li X; Cheng D; Hou Y; Li Y; Li T; Xiao Y; Zhang Q; Rong R
Drug Deliv; 2023 Dec; 30(1):2171158. PubMed ID: 36744299
[TBL] [Abstract][Full Text] [Related]
12. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
[No Abstract] [Full Text] [Related]
13. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
[TBL] [Abstract][Full Text] [Related]
14. Glucose conjugated platinum(II) complex: antitumor superiority to oxaliplatin, combination effect and mechanism of action.
Li H; Gao X; Liu R; Wang Y; Zhang M; Fu Z; Mi Y; Wang Y; Yao Z; Gao Q
Eur J Med Chem; 2015 Aug; 101():400-8. PubMed ID: 26177447
[TBL] [Abstract][Full Text] [Related]
15. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
16. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
[TBL] [Abstract][Full Text] [Related]
18. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
19. Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy.
Ling X; Tu J; Wang J; Shajii A; Kong N; Feng C; Zhang Y; Yu M; Xie T; Bharwani Z; Aljaeid BM; Shi B; Tao W; Farokhzad OC
ACS Nano; 2019 Jan; 13(1):357-370. PubMed ID: 30485068
[TBL] [Abstract][Full Text] [Related]
20. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
